PD-L1 can be constitutively expressed on the surface of cancer cells through poorly characterized oncogenic signalling pathways [19, 20] or alternatively, expressed in response to the presence of CD8+ T cells, producing immune-stimulating cytokines, including IFN-γ [21]. The gene discussed is IFNG; the disease is cancer.